Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mounier, N
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mounier, N
Haematologica, Vol 91, Issue 5, 715-716
Copyright © 2006 by Ferrata Storti Foundation

Letter

Estimating the impact of rituximab on bcl-2-associated resistance to CHOP in elderly patients with diffuse large B-cell lymphoma

N Mounier, J Briere, C Gisselbrecht, F Reyes, P Gaulard, B Coiffier, and

Rituximab plus CHOP (R-CHOP) has been proven to increase overall survival in aggressive bcl-2-positive lymphoma patients. Using competing risk analysis, we studied the long-term impact of this treatment in patients from a GELA trial: R-CHOP prevented from progression or relapse in both bcl-2-positive and bcl-2-negative patients without increasing the risk of death in complete remission.


This article has been cited by other articles:


Home page
 BloodHome page
R. Malumbres, J. Chen, R. Tibshirani, N. A. Johnson, L. H. Sehn, Y. Natkunam, J. Briones, R. Advani, J. M. Connors, G. E. Byrne, et al.
Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP
Blood, June 15, 2008; 111(12): 5509 - 5514.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. H. Wilson, K. Dunleavy, S. Pittaluga, U. Hegde, N. Grant, S. M. Steinberg, M. Raffeld, M. Gutierrez, B. A. Chabner, L. Staudt, et al.
Phase II Study of Dose-Adjusted EPOCH and Rituximab in Untreated Diffuse Large B-Cell Lymphoma With Analysis of Germinal Center and Post-Germinal Center Biomarkers
J. Clin. Oncol., June 1, 2008; 26(16): 2717 - 2724.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
P. Morel, P. Gaulard, C. Gisselbrecht, C. Ferme, G. Salles, H. Tilly, J. Briere, M. C. Copin, P. Lederlin, O. Hermine, et al.
Autologous stem-cell transplantation as consolidation therapy for diffuse large B-cell lymphoma patients with overexpression of bcl-2 protein. Results of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trial LNH98-B2
Ann. Onc., March 1, 2008; 19(3): 560 - 565.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
S. Prakash and S. H Swerdlow
Nodal aggressive B-cell lymphomas: a diagnostic approach
J. Clin. Pathol., October 1, 2007; 60(10): 1076 - 1085.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. O. Armitage
How I treat patients with diffuse large B-cell lymphoma
Blood, July 1, 2007; 110(1): 29 - 36.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
A. R. Jazirehi, M. I. Vega, and B. Bonavida
Development of Rituximab-Resistant Lymphoma Clones with Altered Cell Signaling and Cross-Resistance to Chemotherapy
Cancer Res., February 1, 2007; 67(3): 1270 - 1281.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2006 by the Ferrata Storti Foundation.